Class: Stimulant FDA Indications: ADHD, Narcolepsy Off-Label Use: Treatment Resistant Depression, Depressive Symptoms In Medically-ill Elderly, Post-stroke Depression, Depression, Cognitive Impairment And Severe Fatigue Patients With HIV Infection
FDA Schedule II Forms: 5, 10, 15, 20, 25, 30mg ER Capsules; 5, 7.5, 10, 12.5, 15, 20, 30mg IR Tablets Dose Range: 5-60 mg/day Starting: IR formulation- Initiate at 5 mg qd or bid, ↑ by 5 mg at weekly intervals. Usual max 40 mg daily divided in 1-3 doses; XR formulation- Initiate at 20 mg qam Stopping: Taper to avoid withdrawal Monitoring: Perform a targeted cardiac history, and cardiac exam before initiation. Monitor baseline blood pressure, heart rate, and ECG.
Contraindications: Advanced atherosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated state, hx of drug abuse, use with (or within 14 days of) an MAO inhibitor Serious Side Effects: Serious cardiovascular events. Sudden cardiac death, stroke, and MI. Can exacerbate pre-existing bipolar or psychotic disorder. May lower seizure threshold. Side Effects: nausea, decreased appetite, weight loss, tics, peripheral vasculopathy
1° MOA: Promotes Presynaptic DA & NE Release
Target: VMAT2 (inhibitor),
NET & DAT (competitive inhibitor & pseudosubstrate), MAO (inhibitor, weak)
may ↑ levels and effects of opioids and sympathomimetics
- mixed amphetamine salts, d-amphetamine to l-amphetamine salts in a 3:1 ratio
IR lasts ~4-6°; XR lasts ~8-10°
taking with food can delay Tmax 2-3°
can potentially exacerbate symptoms in patients with pre-existing psychotic disorders or potentially induce mania in bipolar patients
an oral suspension (1 mg/mL) can be made with tablets: crush ten 10 mg tabs to a fine powder, add small portions of Ora-Sweet and mix into a paste, add liquid vehicle to make 100 mL of solution; stable for 30 days, mix well before each use
Category C—Majority of data based on illicit amphetamine and methamphetamine use. May increase risk for premature birth and low birth weight. Newborns may experience withdrawal. Children may experience behavioral problems.
Majority of data based on illicit amphetamine and methamphetamine use. Amphetamine are excreted into breast milk in higher concentrations than present in mothers serum. May decrease milk production. Can cause irritability, agitation, and crying in nursing infants.
Start lower, i.e. 10 mg/d (typical dose is 20 mg/d); consider a 5 mg/d starting dosage for especially frail patients; give second dose mid-afternoon to avoid insomnia
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated June 10 2018 15:40:14. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.
Think before you use this website!
Psychopharmacopeia.com includes clinical information intended for use by healthcare professionals. This does not constitute as clinical or professional advice. Physicians and other healthcare professionals should always use their own clinical judgment first and follow laws and guidelines in their own practice jurisdiction. Psychopharmacopeia.com does not give medical advice or diagnostic services. Neither we nor our content providers can guarantee that the content covers all possible uses, directions, precautions, drug interactions, or adverse effects that may be associated with any therapeutic treatments.
Non-health care providers who use this website, please do so at your own risk, and always seek professional medical advice. I have done my best to ensure that the information on this website is reliable, but neither we nor our content providers guarantee the accuracy of the information contained on this site.
Use this site at your own risk. Psychopharmacopeia.com and its hosting provider do not assume any liability or responsibility for damage, injury, or death to you, other persons or property from any use of any ideas, information, or instruction in this website.